Phase II Pre-Surgical Intervention Study for Evaluating the Effect of Metformin on Breast Cancer Proliferation
The purpose of this pilot study is to use a pre surgical intervention model to evaluate the
biologic effects of metformin in women with newly diagnosed early invasive breast cancer.
Metformin is a biguanide derivative which is commonly used to treat patients with diabetes.
This model will be used to evaluate the effects of metformin on a specific molecular pathway
called the AMPK/mTOR signaling pathway in the tumor. The effects of metformin on serum
insulin levels and components of the insulin resistance syndrome will also be studied.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Effects of metformin on AMPK/mTOR signaling pathway
2 weeks
Yes
Dawn L Hershman, MD
Principal Investigator
Columbia University
United States: Institutional Review Board
AAAD6525
NCT00930579
October 2009
March 2014
Name | Location |
---|---|
Columbia University Medical Center | New York, New York 10032 |